Bio-Techne stock kpis
Want to see TECH full AI Analyst Report?
Adjusted Operating Income by Segment
Bio-Techne reported adjusted operating income by segment of $5.90M in Q1 FY2027, down 41.4% from Q4 FY2026 and down 33.6% year over year. The highest value was $19.41M in Q3 FY2022.
Presents segment profits after removing one-time charges and accounting adjustments to reveal underlying operating performance. Helps you judge the durability of margins and whether reported improvements reflect real efficiency gains or temporary items.
Diagnostics & Spatial Biology has been highly lumpy—periodic large swings and a pronounced mid‑2023 trough point to one‑off timing, product mix, or acquisition-related effects rather than steady organic growth. The past several quarters show a clearer, sustained upswing, suggesting operational normalization and reduced downside risk versus the 2023 disruption. Still, the historical volatility implies earnings remain sensitive to project timing and mix; treat short‑term quarters as noisy until management demonstrates durable margin improvements or steadier revenue drivers.
TECH Adjusted Operating Income by Segment
| Period | Diagnostics and Spatial Biology |
|---|---|
| Q1 FY2027Sep 30, 2026 | $5.90M |
| Q4 FY2026Jun 30, 2026 | $10.07M |
| Q3 FY2026Mar 31, 2026 | $10.32M |
| Q2 FY2026Dec 31, 2025 | $8.43M |
| Q1 FY2026Sep 30, 2025 | $8.88M |
| Q4 FY2025Jun 30, 2025 | $5.38M |
| Q3 FY2025Mar 31, 2025 | $8.42M |
| Q2 FY2025Dec 31, 2024 | $3.24M |
| Q1 FY2025Sep 30, 2024 | $4.28M |
| Q4 FY2024Jun 30, 2024 | $11.36M |
| Q3 FY2024Mar 31, 2024 | $8.10M |
| Q2 FY2024Dec 31, 2023 | $4.56M |
| Q1 FY2024Sep 30, 2023 | $527.00K |
| Q4 FY2023Jun 30, 2023 | $14.64M |
| Q3 FY2023Mar 31, 2023 | $11.46M |
| Q2 FY2023Dec 31, 2022 | $8.30M |
| Q1 FY2023Sep 30, 2022 | $8.64M |
| Q4 FY2022Jun 30, 2022 | $11.23M |
| Q3 FY2022Mar 31, 2022 | $19.41M |
| Q2 FY2022Dec 31, 2021 | $10.88M |
| Q1 FY2022Sep 30, 2021 | $7.46M |
| Q4 FY2021Jun 30, 2021 | $11.23M |
| Q3 FY2021Mar 31, 2021 | $10.42M |
| Q2 FY2021Dec 31, 2020 | $8.11M |
| Q1 FY2021Sep 30, 2020 | $8.67M |

